Table 1.
Patient characteristics.
| Characteristics | n (%) |
|---|---|
| Age (mean) | 72.5 (range, 61–83) |
| Primary t stage | |
| T1a–c | 1(2.4%) |
| T2a–c | 23(56.1%) |
| T3a | 8(19.5%) |
| T3b | 9(21%) |
| Clinical nodal status | |
| N0 | 41(100%) |
| Gleason score | |
| ≤6 | 10(24.4%) |
| =7 | 14(34.1%) |
| ≥8 | 17(41.5%) |
| PSA level (ng/ml) | |
| Median | 44.15 (range, 4.51–250.32) |
| ≤10 | 7(17.1%) |
| 10–20 | 9(21.9%) |
| >20 | 25(61.0%) |
| NCCN risk group | |
| High-risk | 32(78.1%) |
| Very high-risk | 9(21.9%) |
| Hormone therapy | |
| Neoadjuvant | 22(53.7%) |
| Concurrent | 16(39.0%) |
| No | 3(7.3%) |
| IPSSa (Pre-treatment) | |
| 0–7 | 13(33.3%) |
| 8–19 | 16(41.0%) |
| 20–35 | 10(25.7%) |
| IIEFa (Pre-treatment) | |
| 0 | 21(53.8%) |
| ≤21 | 38(97.4%) |
| ≥22 | 1(2.6%) |
IPSS, international prostate symptom score; IEFF, international index of erectile function questionnaire.
aOnly 39 patients completed the questionnaires.